An overview of recent findings of the Stanley Foundation Bipolar Network (Part I)

Bipolar Disorders

Volumn 5, Issue 5, 2003, Pages 310-319

  Post, Robert M ^a   Leverich, Gabriele S ^a   Altshuler, Lori L ^b   Frye, Mark A ^b   Suppes, Trisha M ^c   Keck Jr , Paul E ^d   McElroy, Susan L ^d   Kupka, Ralph ^e   Nolen, Willem A ^e   Grunze, Heinz ^f   Walden, Jorg ^g  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Anticonvulsants; Antidepressants; Bipolar disorder; Course of illness; Depression; Episode sensitization; Lithium; Mania; Mood stabilizers; Rapid cycling; Stanley Foundation Bipolar Network

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CLOZAPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; ETIRACETAM; GABAPENTIN; ICOSAPENTAENOIC ACID; LAMOTRIGINE; LITHIUM; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN 1A AGONIST; SERTRALINE; SIBUTRAMINE; THYROID ANTIBODY; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VENLAFAXINE; ZONISAMIDE;

BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG RESPONSE; EUROPE; EXTRAPYRAMIDAL SYNDROME; HUMAN; HYPOMANIA; HYPOTHYROIDISM; MANIA; MEDICAL RESEARCH; MORBIDITY; OBESITY; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SUICIDE ATTEMPT; TARDIVE DYSKINESIA; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; DRUG INTERACTIONS; FATTY ACIDS, OMEGA-3; FOUNDATIONS; HUMANS; INFORMATION SERVICES; META-ANALYSIS; RISK FACTORS; THYROID DISEASES;

EID: 0242363788     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2003.00051.x     Document Type: Review

References (60)

1. Post RM, Nolen WA, Kupka RW et al. The Stanley Foundation Bipolar Network: 1. Rationale and methods. Br J Psychiatry 2001; 178: S169-S176.
2. Leverich GS, Nolen WA, Rush AJ et al. The Stanley Foundation Bipolar Treatment Outcome Network. I. Longitudinal methodology. J Affect Disord 2001; 67: 33-44.
3. Leverich GS, Post RM. Life charting the course of bipolar disorder. Current Review of Mood and Anxiety Disorders 1996; 1: 48-61.
4. Leverich GS, Post RM. Life charting of affective disorders. CNS Spectrums 1998: 3: 21-37.
5. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
6. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns CA. The inventory for depressive symptomatology (IDS): preliminary findings. Psychiatr Res 1986; 18: 65-87.
7. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996: 26: 477-486.
8. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
9. Suppes T, Leverich GS, Keck PE et al. The Stanley Foundation Bipolar Treatment Outcome Network. II. Demographics and illness characteristics of the first 261 patients. J Affect Disord 2001; 67: 45-59.
10. McElroy SL, Altshuler LL, Suppes T et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001; 158: 420-426.
11. Post RM, Altshuler LL, Frye MA et al. Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disorders 2001; 3: 259-265.
12. McElroy SL, Suppes T, Keck PE et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry 2000; 47: 1025-1033.
13. Altshuler LL, Keck PE Jr, McElroy SL et al. Gabapentin in the acute treatment of refractory bipolar disorder. Bipolar Disorders 1999; 1: 61-65.
14. Suppes T, Brown ES, McElroy SL et al. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affective Disord 1999; 53: 95-98.
15. Suppes T, Chisholm KA, Dhavale D et al. Tiagabine in treatment refractory bipolar disorder: a clinical case series. Bipolar Disord 2002; 4: 283-289.
16. Post RM, Altshuler LL, Frye MS et al. An overview of recent findings of the Stanley Foundation Bipolar Network (SFBN) (Part II): Focus on anticonvulsants. Bipolar Disord 2003; in press.
17. McElroy SL, Frye M, Denicoff K et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998; 49: 119-122.
18. Keck PE Jr. New antiepileptics in the treatment of bipolar disorder. Syllabus and Proceedings Summary of the 2001 American Psychiatric Association Meeting, New Orleans, May 5-10 Abstract 34E, 93. 2001.
19. Post RM, Denicoff KD, Leverich GS et al. Morbidity in 258 bipolar outpatients followed for one year with daily prospective ratings on the NIMH Life Chart Method. J Clin Psychiatry 2003; 64: 680-690.
20. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
21. O'Connell RA, Mayo JA, Flatow L, Cuthbertson B, O'Brien BE. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123-129.
22. Vestergaard P, Licht RW, Brodersen A et al. Outcome of lithium prophylaxis: a prospective follow-up of affective disorder patients assigned to high and low serum lithium levels. Acta Psychiatr Scand 1998; 98: 310-315.
23. Gelenberg AJ, Kane JM, Keller MB et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 1489-1493.
24. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
25. Coryell W, Winokur G, Solomon D, Shea T, Leon A, Keller M. Lithium and recurrence in a long-term follow-up of bipolar affective disorder. Psychol Med 1997; 27: 281-289.
26. Judd LL, Akiskal HS, Schettler PJ et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002; 59: 530-537.
27. Goldberg JF, Harrow M, Leon AC. Lithium treatment of bipolar affective disorders under naturalistic followup conditions. Psychopharmacol Bull 1996; 32: 47-54.
28. Altshuler L, Kiriakos L, Calcagno J et al. The impact of antidepressant discontinuation versus antidepressant continuation on 1-year risk for relapse of bipolar depression: a retrospective chart review. J Clin Psychiatry 2001; 62: 612-616.
29. Altshuler L, Suppes T, Black D et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at one-year follow-up. Am J Psychiatry 2003; 160: 1252-1262.
30. Leverich GS, McElroy SL, Suppes T et al. Early physical and sexual abuse associated with an adverse course of bipolar illness. Biol Psychiatry 2002; 51: 288-297.
31. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149: 999-1010.
32. Post RM, Weiss SRB, Leverich GS, Smith M, Zhang LX. Sensitization and kindling-like phenomena in bipolar disorder: implications for psychopharmacology. Clin Neurosci Res 2001; 1: 69-81.
33. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry 1998; 172: 23-28.
34. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the "kindling" hypothesis. Am J Psychiatry 2000; 157: 1243-1251.
35. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001; 158: 582-586.
36. Plotsky PM, Meaney MJ. Early, postnatal experience afters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Mol Brain Res 1993; 18: 195-200.
37. Kaufman J, Plotsky PM, Nemeroff CB, Charney DS. Effects of early adverse experiences on brain structure and function: clinical implications. Biol Psychiatry 2000; 48: 778-790.
38. Leverich GS, Altshuler LL, Frye MA et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003; 64: 506-515.
39. Frye MA, Altshuler LL, McElroy SL et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 2003; 160: 883-889.
40. McElroy SL, Frye MA, Suppes T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder. J Clin Psychiatry 2002; 63: 207-213.
41. Hunt N, Silverstone T. Tardive dyskinesia in bipolar affective disorder: a catchment area study. Int Clin Psychopharmacol 1991; 6: 45-50.
42. Kupka RW, Nolen WA, Post RM et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry 2002; 51: 305-311.
43. Spencer CA, Takeuchi M, Kazarosyan M et al. Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998; 83: 1121-1127.
44. Post RM, Kramlinger KG, Joffe RT et al. Rapid cycling bipolar affective disorder: lack of relation to hypothyroidism. Psychiatry Res 1997; 72: 1-7.
45. Stoll AL, Severus WE, Freeman MP et al. Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-412.
46. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-479.
47. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002; 59: 913-919.
48. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 12: 56-62.
49. Denicoff KD, Smith-Jackson EE, Disney ER, Suddath RL, Leverich GS, Post RM. Preliminary evidence of the reliability and validity of the prospective life-chart methodology (LCM-p). J Psychiatr Res 1997; 31: 593-603.
50. Denicoff KD, Leverich GS, Nolen WA et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 2000; 30: 1391-1397.
51. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187-190.
52. Prien RF, Caffey EMJ, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974; 31: 189-192.
53. Sarantidis D, Waters B. Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol 1981; 5: 507-510.
54. Abou-Saleh MT, Coppen A. Who responds to prophylactic lithium? J Affect Disord 1986; 10: 115-125.
55. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
56. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264-1266.
57. Obrocea GV, Dunn RM, Frye MA et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253-260.
58. Nolen WA, Luckenbaugh DA, Altshuler LL et al. Correlates of one year prospective outcome in bipolar disorder: results from the Stanley Foundation Bipolar Network. Am J Psychiatry 2003; in press.
59. Colom F, Vieta E, Martinez-Aran A et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003; 60: 402-407.
60. Sachs GS, Thase ME, Otto MW et al. Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 2003; 53: 1028-1042.